TRPX Snapshot
Therapix Biosciences Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include THX-110, which has completed Phase II a clinical trial for the treatment of Tourette syndrome and Obstructive Sleep Apnea; THX-160, which has completed two preliminary preclinical studies for the treatment of acute and chronic pain; and THX-210 for the treatment of autism spectrum disorder and epilepsy. The company was formerly known as NasVax Ltd. and changed its name to Therapix Biosciences Ltd. in November 2013. Therapix Biosciences Ltd. was founded in 2004 and is headquartered in Givatayim, Israel.
Market Capitalization$2,019
Price to Sales0.00
Earnings per Share$0.0000
PE Ratio-8826250
Most Recent Close$0.1000
52 Week High$0.3855
52 Week Low$9.25
50-Day Moving Average$0.072
200-Day Moving Average$3.7154
All data are from Alpha Vantage as of today. For more infomation on TRPX see Stock Dividend, Valuation, Price and Financial Data for Investors